EnteroBiotix Private Investor Briefing - NYC

​Dear Investors,

​EnteroBiotix is advancing a new generation of microbiome-based therapeutics, with its lead program now entering Phase 2b development for irritable bowel syndrome (IBS).

​Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing featuring EnteroBiotix and EBX-102-02®, an investigational oral therapy being developed for IBS-C.

​Following positive Phase 2a results, EnteroBiotix has advanced EBX-102-02 into Phase 2b, with its RISE study now underway in approximately 300 patients. Topline efficacy data are anticipated in H2 2027.

​Why Investors Are Taking Notice

• ​Clinical Momentum: Positive Phase 2a results followed by a 300-patient Phase 2b study.

• ​Large Patient Population: IBS affects approximately 11% of the global population, with more than $10B in direct annual U.S. healthcare costs.

• ​Recent Financing: EnteroBiotix raised £19M ($25M) to advance EBX-102-02 into Phase 2b.

• ​Broader Pipeline: Additional microbiome programs are being developed in liver disease and blood cancer.

​Learn more about EnteroBiotix, its clinical progress, and the development path for EBX-102-02.

​Event Details:

​Date: October 14, 2026
Time: 5:30 - 7:30 pm EDT
Location: New York City

​Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval.

​Request investor materials by contacting Skylar Rallison at srallison@opus8.com.

​Thanks much and all the best,

​Tien Wong
CEO
Opus8, Inc.